Compared · Gene2Rx
Gene2Rx reads more pharmacogenes from a VCF than we do. Here is where the VCF stops.
Gene2Rx is a pharmacogenetics-only service. From a whole-genome VCF it covers 118 medications for $64, in under a minute, and it reads more pharmacogenes from a VCF than we do. Counted per dollar, it comes out ahead on a plain VCF and behind on a gVCF. This page says that first. Its own guide then names the limit that decides the rest.
Where Gene2Rx wins
More genes from a VCF. Its homepage lists a $49 Complete Pharmacogenetics Report covering "118 medications with genetic drug testing", with "All 34 drug classes analyzed" and "an additional $15 per report" for a whole-genome VCF, so $64 all in. The homepage counts "27 pharmacogenes"; the table on its GeneSight comparison page lists 29 gene symbols. From a plain VCF alone, our whole-genome report resolves 9 pharmacogenes to CPIC's allele definitions and refuses the rest; from a gVCF it resolves 25, because a gVCF records which positions were examined and a plain VCF does not, and every one of those cards states how many of the gene's defining positions the file actually called. If a plain VCF is all you hold and pharmacogenomics is all you want, Gene2Rx gives you more genes for your money: 27 for $64, against 9 for $39 here. From a gVCF the gene counts are close, 27 against 25, and ours costs less.
Speed and a subscription that makes sense. "Get your pharmacogenetics report in under 1 minute after upload", and a $20-a-year Pro tier that regenerates the report as new versions ship. Our whole-genome report takes about a quarter of an hour and its re-analysis subscription is $12 a year.
Plain disclaimers. Its homepage repeats that direct-to-consumer data "is not clinical grade", and tells you to "use your report only as a conversation starter". We say the same thing in our own words, and we credit a competitor that says it clearly.
Where the two differ
| Gene2Rx | Aimosti | |
|---|---|---|
| Price | $49 Complete report, +$15 for a WGS VCF = $64; $35 psychiatric; $5 starter; Pro $20/year (its homepage) | $39 whole-genome report including VCF pharmacogenomics; $49 Deep Read reads panel; $69 together |
| What it reads | Array exports and "VCF from any provider", GRCh37 or GRCh38; no BAM, CRAM or FASTQ mentioned (its homepage) | Chip exports, VCF, gVCF, and BAM or CRAM for the reads panel |
| Pharmacogenes | "27 pharmacogenes" (homepage) or 29 (its GeneSight comparison table), 118 medications, CPIC and FDA guidance | 9 from a plain VCF, 25 from a gVCF; 29 from reads to CPIC star-allele resolution, from a pinned CPIC snapshot |
| CYP2D6 copy number | "does not detect copy-number changes such as CYP2D6 gene duplications or deletions, which require raw alignment files" (its Nucleus and Sequencing.com guides) | Called from the reads, duplications, deletions and hybrids included |
| HLA | "does not currently report HLA alleles" (its Nucleus guide) | HLA-B*57:01 (from a chip or a sequenced file) and B*15:02 (from a sequenced file) inferred from tag variants, labelled as inferred; HLA-DQA1/DQB1 typed from reads for celiac risk |
| Coverage | Reads the variant calls in the VCF | Per-gene callability measured from the reads; a gene the reads cannot cover is declined |
| Beyond pharmacogenomics | None; it is a pharmacogenetics report | Clinical findings, carrier status, traits, ancestry and polygenic scores from the same file |
| Where the file goes | Processed in the United States on AWS; report and file kept "unless otherwise requested", opt-out deletes within 24 hours (its privacy policy) | Processed and stored in Finland; deleted after analysis by default; reads deleted when the run finishes |
| Entity | "GENOME ANALYTICS L.L.C." in its terms; no address or governing law published | Aimosti Oy, Finland |
What the reads add, in Gene2Rx's own words
The sentence to read twice is theirs: copy-number changes in CYP2D6 "require raw alignment files". That gene shapes the dosing of common antidepressants, painkillers and tamoxifen, and its duplications, deletions and pseudogene hybrids are exactly what a variant list cannot represent. Deep Read reads them from the BAM or CRAM, and does the same for the other structurally awkward genes in the panel, then measures how much of each gene was actually covered. It ends in a one-page hand-off for a prescriber. Where a VCF can call a gene honestly, we call it from the VCF; where it cannot, we say so instead of printing a diplotype that looks confident.
If you hold only a VCF and want the longer pharmacogene list, buy Gene2Rx. If you hold the reads, the answer to the question its guide raises is the panel here.
Gene2Rx is described from its own public pages as read on 15 October 2026. Prices are quoted as displayed that day, in the currency shown there, and features change. We do not speak for Gene2Rx. If something here is out of date, tell us and we will correct it.
Hold a BAM or CRAM? See what the reads panel returns before you decide.
Other comparisons: Promethease · Genetic Lifehacks · SelfDecode · Sequencing.com · all five